Please be informed that the Committee, at its meeting on 5-6 prices and reimbursement November 2014 has delivered a negative opinion on the new listings for the following indication: pulmonary arterial hypertension (pulmonary arterial hypertension, PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, it is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with CF who functional class II to III to improve the capacity of exercise. The efficacy has been shown in patients with hereditary or idiopathic PAH or PAH associated with connective tissue disorders.
Search Translated Laws of Italy
Made in Toronto, Canada
Global-Regulation Inc. is a Canadian federal corporation based in Toronto, Canada.
19 Yorkville Avenue, Suite 300
Toronto, ON, Canada
Our service is entirely run by computer algorithms. Translations are not human-vetted. There may be inaccuracies in information due to our algorithmic extraction of information. Always consult the official source when making use of legal information.